{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-263543","form_type":"8-K","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.525434+00:00","generated_at":"2026-05-17T00:41:03.435190+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Taysha Gene Therapies: TSHA-102 gets FDA Breakthrough Therapy, Q3 net loss $32.7M","bullets":["FDA granted Breakthrough Therapy designation for TSHA-102 in Rett syndrome; FDA alignment finalized on REVEAL pivotal trial protocol with 6-month interim analysis to expedite BLA.","First patient dosing in REVEAL pivotal trial scheduled Q4 2025; enrollment to continue at multiple sites.","Regained full unencumbered rights to TSHA-102 after Astellas option agreement expired in October 2025.","Q3 2025 net loss $32.7M ($0.09/share); R&D $25.7M; cash $297.3M expected to fund operations into 2028.","David McNinch appointed Chief Commercial Officer in September 2025; TSHA-102 generally well tolerated with no treatment-related SAEs in 12 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-263543","json":"https://secwatch.observer/filing/0001193125-25-263543.json","markdown":"https://secwatch.observer/filing/0001193125-25-263543.md","text":"https://secwatch.observer/filing/0001193125-25-263543.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/0001193125-25-263543-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312525263543/d17004d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:41:03.435190+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}